-
41
-
42
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Baskı/Yayın Bilgisi 2025Konular: -
43
-
44
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Baskı/Yayın Bilgisi 2025Konular: -
45
Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Baskı/Yayın Bilgisi 2025Konular: -
46
-
47
Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Baskı/Yayın Bilgisi 2025Konular: -
48
Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
49
Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
50
Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
51
Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
52
Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
53
Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
54
Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
55
Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Baskı/Yayın Bilgisi 2025Konular: -
56
Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Baskı/Yayın Bilgisi 2025Konular: -
57
Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Baskı/Yayın Bilgisi 2025Konular: -
58
Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Baskı/Yayın Bilgisi 2025Konular: -
59
Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
Baskı/Yayın Bilgisi 2025Konular: -
60
Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Baskı/Yayın Bilgisi 2025Konular: